Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donata Backhaus

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Environmental Science and Pollution Research International|May 17, 2011
Pharmaceuticals in the environment: an educational perspectiveMarco Eissen, Donata Backhaus
Hemasphere|February 22, 2021
Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell TransplantationDominic Brauer, Donata Backhaus, Rosmarie Pointner, et al.
Cancers|February 25, 2023
Clinical Implications of the <i>FLT3</i>-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell TransplantationMadlen Jentzsch, Lara Bischof, Dominic Brauer, et al.
Annals of Hematology|August 31, 2020
Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AMLMadlen Jentzsch, Marius Bill, Juliane Grimm, et al.
Bone Marrow Transplantation|November 19, 2020
ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantationMadlen Jentzsch, Juliane Grimm, Marius Bill, et al.
Bone Marrow Transplantation|October 4, 2022
A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or olderDonata Backhaus, Dominic Brauer, Rosmarie Pointner, et al.
Blood Advances|May 23, 2022
Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remissionMadlen Jentzsch, Lara Bischof, Donata Backhaus, et al.
Cancers|November 27, 2021
Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell TransplantationDonata Backhaus, Madlen Jentzsch, Lara Bischof, et al.
American Journal of Hematology|July 21, 2021
Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantationJuliane Grimm, Madlen Jentzsch, Marius Bill, et al.
Blood Cancer Journal|December 18, 2022
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantationMadlen Jentzsch, Lara Bischof, Jule Ussmann, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Environmental Science and Pollution Research International|May 17, 2011
Pharmaceuticals in the environment: an educational perspectiveMarco Eissen, Donata Backhaus
Hemasphere|February 22, 2021
Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell TransplantationDominic Brauer, Donata Backhaus, Rosmarie Pointner, et al.
Cancers|February 25, 2023
Clinical Implications of the <i>FLT3</i>-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell TransplantationMadlen Jentzsch, Lara Bischof, Dominic Brauer, et al.
Annals of Hematology|August 31, 2020
Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AMLMadlen Jentzsch, Marius Bill, Juliane Grimm, et al.
Bone Marrow Transplantation|November 19, 2020
ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantationMadlen Jentzsch, Juliane Grimm, Marius Bill, et al.
Bone Marrow Transplantation|October 4, 2022
A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or olderDonata Backhaus, Dominic Brauer, Rosmarie Pointner, et al.
Blood Advances|May 23, 2022
Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remissionMadlen Jentzsch, Lara Bischof, Donata Backhaus, et al.
Cancers|November 27, 2021
Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell TransplantationDonata Backhaus, Madlen Jentzsch, Lara Bischof, et al.
American Journal of Hematology|July 21, 2021
Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantationJuliane Grimm, Madlen Jentzsch, Marius Bill, et al.
Blood Cancer Journal|December 18, 2022
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantationMadlen Jentzsch, Lara Bischof, Jule Ussmann, et al.
Pageof 2